Summary of benefits

NAFTIN® (Naftifine HCl) Gel, 2%: An antifungal that successfully treats the most common dermatophyte infections1,5,6

Trichophyton rubrum
Trichophyton mentagrophytes
Epidermophyton floccosum

Let your patients experience all the benefits of NAFTIN® Gel, 2%

  • Proven antifungal efficacy with once-daily, 2-week dosing1
  • A fungicidal allylamine that attacks offending microorganisms1
  • Highest efficacy observed at 6 weeks (4 weeks post last treatment) with NAFTIN® Gel, 2%1
  • Adverse events comparable to vehicle1
    • Application site reactions were the most common adverse reactions seen in clinical trials with NAFTIN® Gel, 2%1
  • Aqueous-based gel, which has excellent penetration properties and is rapid drying1,7
Learn more
ExpandCollapseClick to See Complete Safety InformationClose

NAFTIN® (Naftifine HCl) Gel, 2%

INDICATIONS AND USAGE

NAFTIN GEL, 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION ADVERSE REACTIONS

In clinical trials with NAFTIN Gel, 2%, the most common adverse reactions (2%) were application site reactions.

WARNINGS AND PRECAUTIONS

If redness or irritation develops with the use of NAFTIN Gel, 2%, treatment should be discontinued.

Please click here for NAFTIN full prescribing information

References: 1. NAFTIN® Gel (Naftifine HCI), 2% Prescribing Information. Greensboro, NC: Merz Pharmaceuticals, LLC; October 2014. 2. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:S3-S8. 3. NAFTIN 2% Co-Pay Savings Offer. Sebela Pharmaceuticals Inc., January 2017. 4. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration/Center for Drug Evaluation and Research website. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=019599&TABLE1=OB_Rx. Accessed February 22, 2016. 2015. 5. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. November 2011;10(11):1282-1288. 6. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. October 2011;10(10):1142-1147. 7. Vlahovic TC. Choosing the right vehicle. Podiatry management. June/July 2008;209-218. 8. Robbins CM, Elston DM. Tinea pedis treatment & management. Medscape Web site. http://emedicine.medscape.com/article/1091684-overview. Updated November 19, 2015. Accessed February 22, 2016. 9. Phillips, RM, Rosen T. Topical antifungal agents. Allylamines and benzylamines. In: Wolverton, SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed. Elsevier Inc. Ebook; 2013:460-472.